Fintech PR
Cboe Global Listings Reaches New Milestone Surpassing 1,000 ETFs Listed Across its Global Network
- Latest milestone marks continued progress in Cboe’s mission to build a global listings network and expand the investable universe for investors
- Cboe welcomed 106 new ETF securities across its global network of listings exchanges in the first quarter of 2024
- More than 120 issuer partners currently list ETF products on Cboe’s global network of stock exchanges in the U.S., Canada, UK, European Union, and Australia
CHICAGO, April 2, 2024 /PRNewswire/ — Cboe Global Markets, Inc. (Cboe: CBOE), the world’s leading securities and derivatives exchange network, today announced that it has achieved a new milestone, surpassing more than 1,000 exchange traded funds (ETFs) listed across its global network of listings exchanges.
“This ETF listings milestone is another major step forward in building our global listings business. It’s a testament to Cboe’s continued innovation in the ETF ecosystem and focus on customer-centric service and support,” said Dave Howson, Executive Vice President, Global President, Cboe Global Markets. “From industry-leading market intelligence and technology, to a global liquidity provision program and 50 years of experience as a company, we provide our issuer partners with an innovative, collaborative, and seamless approach to global account management when listing with Cboe.”
Rob Marrocco, Vice President, Global Head of ETF Listings, Cboe Global Markets, said: “As evidenced by this latest milestone, we continue to make steady progress in growing our global listings business. We appreciate the continued support from our more than 120 ETF issuer partners around the world who believe in our mission to redefine the listing experience. And we are grateful they have placed their trust and confidence in Cboe as the listing venue of choice for more than 1,000 ETFs, enabling us to continue to expand the investable universe for investors.”
Cboe’s roster of over 1,000 ETFs includes a variety of purpose-driven funds that make innovative investment strategies accessible to all investors, including ETFs with a derivatives overlay, such as defined outcome and buy-write ETFs, thematic ETFs, including the recently listed spot bitcoin ETFs, ETFs resulting from mutual fund conversions, and many others.
In the first quarter of 2024, Cboe listed 106 new ETF securities globally, with 50 in the U.S., 40 in Canada, 10 in the UK and the European Union, and six in Australia. Included among the new U.S. listings in January were six spot bitcoin ETFs, which currently represent approximately $13 billion of AUM.
Cboe is the only exchange network in the world facilitating access to global capital and secondary liquidity, by offering a seamless path for purpose-driven companies and asset managers to intralist across its network of stock exchanges in the U.S., Canada, the UK, the European Union, and Australia. Through this exchange network, Cboe is building the first-ever global listings experience for companies and ETFs. In February, BlackRock became the first asset manager to have ETFs listed across Cboe’s entire network of exchanges with the launch of new iShares by BlackRock Factor ETFs listed for trading on Cboe Australia.
Cboe is currently the second largest ETF listing venue in the U.S. with more than 690 ETF listings. Cboe Europe is the first Pan-European listing venue for ETFs, and currently offers approximately 120 listings. Cboe Canada is home to more than 275 listings including public companies, ETFs, and Canadian Depositary Receipts (CDRs). There are more than 20 ETFs and 1,000 other investment products quoted on Cboe Australia, which currently captures up to 40 percent of the Australian ETF daily trading volume.
Additional information on Cboe’s global listings can be found at Cboe Listings.
About Cboe Global Markets
Cboe Global Markets (Cboe: CBOE), the world’s leading derivatives and securities exchange network, delivers cutting-edge trading, clearing and investment solutions to people around the world. Cboe provides trading solutions and products in multiple asset classes, including equities, derivatives, FX, and digital assets, across North America, Europe and Asia Pacific. Above all, we are committed to building a trusted, inclusive global marketplace that enables people to pursue a sustainable financial future. To learn more about the Exchange for the World Stage, visit www.cboe.com.
|
Media Contacts |
Analyst Contact |
||||
|
Cboe U.S. Angela Tu |
Cboe Europe Tim Cave |
Cboe U.S. Kenneth Hill, CFA |
|||
|
+1 646-856-8734 |
+44 (0) 7593-506-719 |
+1 312-786-7559 |
|||
CBOE-C
CBOE-OE
Cboe®, and Cboe Global Markets® are registered trademarks of Cboe Exchange, Inc. All other trademarks and service marks are the property of their respective owners.
Cboe Global Markets, Inc. and its affiliates do not recommend or make any representation as to possible benefits from any securities, futures or investments, or third-party products or services. Cboe Global Markets, Inc. is not affiliated with iShares or BlackRock. Investors should undertake their own due diligence regarding their securities, futures and investment practices. This press release speaks only as of this date. Cboe disclaims any duty to update the information herein.
Nothing in this announcement should be considered a solicitation to buy or an offer to sell any securities or futures in any jurisdiction where the offer or solicitation would be unlawful under the laws of such jurisdiction. Nothing contained in this communication constitutes tax, legal or investment advice. Investors must consult their tax adviser or legal counsel for advice and information concerning their particular situation.
Cboe Global Markets, Inc. and its affiliates, to the maximum extent permitted by applicable law, make no warranty, expressed or implied, including, without limitation, any warranties as of merchantability, fitness for a particular purpose, accuracy, completeness or timeliness, the results to be obtained by recipients of the products and services described herein, or as to the ability of the indices named in this press release to track the performance of the general market or any segment thereof, and shall not in any way be liable for any inaccuracies or errors. Cboe Global Markets, Inc. and its affiliates have not calculated, composed or determined the constituents or weightings of the securities that comprise the indices named in this press release and shall not in any way be liable for any inaccuracies or errors.
Cautionary Statements Regarding Forward-Looking Information
Certain information contained in this press release may constitute forward-looking statements. We caution readers not to place undue reliance on any forward-looking statements, which speak only as of the date made and are subject to a number of risks and uncertainties.
Logo – https://mma.prnewswire.com/media/622233/4625970/Cboe_GM_New_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/cboe-global-listings-reaches-new-milestone-surpassing-1-000-etfs-listed-across-its-global-network-302105697.html
STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.
The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.
To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.
The webcast can be followed live here and a recording will be available afterwards.
Information on EQT AB’s financial reporting
The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.
The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.
Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]
Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826
The following files are available for download:
|
Invitation to presentation of EQT AB’s Q1 Announcement 2024 |
|
|
EQT AB Group |
View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html
- Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
- Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
- Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
- Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
- PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
- Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
- 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
- CEO reaffirms Kia’s commitment to ESG management
SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.
Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.
During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.
The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.
“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”
Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html
VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.
As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.
The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.
Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054
Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html
-
Latest News4 days ago
Letter from Gatemore Capital Management LLP to Elementis PLC
-
Latest News4 days ago
Shanghai Electric Releases ESG Report, Highlighting Sustainable Development Achievements in 2023
-
Latest News7 days ago
Stripe Unveils Unbundled Payments Strategy in Fintech Pivot
-
Latest News4 days ago
Hyosung Heavy Industries Ranked on BNEF’s Energy Storage Tier 1 List
-
Latest News6 days ago
Former Tesla executive Tim Newell is set to spin off Aspiration’s consumer financial services division.
-
Latest News4 days ago
Talino, Chemonics invest in startup Higala, the Philippines’ pioneering inclusive instant payment system
-
Latest News6 days ago
United Imaging Healthcare releases 2023 annual report, with revenue growth of 23.52%
-
Latest News7 days ago
Indian fintech firm Aurionpro has expanded its artificial intelligence (AI) capabilities with the acquisition of Arya.ai for $16.5 million.